A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

NCT03813238 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Cerebral Palsy, Dyskinetic

Interventions

DRUG: TEV-50717
DRUG: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.